Literature DB >> 12767016

Studies of neutralising antibodies to SV40 in human sera.

P Minor1, P Pipkin, Z Jarzebek, W Knowles.   

Abstract

It has been suggested that the low levels of antibody to the simian polyoma virus SV40 found in human sera may be linked to the use of polio vaccines. Panels of sera from areas of the world with different vaccination histories were examined to see if consistent differences could be identified. In a total of 2,054 sera from the United Kingdom, 692 from Africa and 923 from Poland taken between 1985 and 1997, the seroprevalence was generally between 3 and 5%, although exceptionally one collection from Morocco had a prevalence of 100%, and one from Poland of 0.4%. The seroprevalence showed no obvious age-dependent increase and titres were low compared to post infection animal sera. The results are consistent with previous studies and reveal no general geographically based differences related to possible differences in vaccination history, but the origin of the SV40 antibody in human sera remains to be established. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767016     DOI: 10.1002/jmv.10422

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  SV40 seroprevalence in two Latin American countries involved in field trials of candidate oral poliovaccines.

Authors:  Connie Wong; Shaojie Zhang; Ervin Adam; Lawrence Paszat; Janet S Butel
Journal:  J Infect       Date:  2019-04-06       Impact factor: 6.072

2.  Complete nucleotide sequence of polyomavirus SA12.

Authors:  Paul Cantalupo; Adrienne Doering; Christopher S Sullivan; Achintya Pal; K W C Peden; Andrew M Lewis; James M Pipas
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis.

Authors:  Tatiana Ribeiro; Maxime J Fleury; Enrico Granieri; Massimiliano Castellazzi; Fernanda Martini; Elisa Mazzoni; Pierre Coursaget; Mauro Tognon
Journal:  Neurol Sci       Date:  2010-06-15       Impact factor: 3.307

Review 4.  Emergent human pathogen simian virus 40 and its role in cancer.

Authors:  Regis A Vilchez; Janet S Butel
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

5.  Ethnic differences in polyomavirus simian virus 40 seroprevalence among women in Houston, Texas.

Authors:  Connie Wong; Regis A Vilchez; Jorge Quiroz; Ervin Adam; Janet S Butel
Journal:  J Infect       Date:  2012-08-30       Impact factor: 6.072

6.  Mesothelioma mortality in Europe: impact of asbestos consumption and simian virus 40.

Authors:  Katharina Leithner; Andreas Leithner; Heimo Clar; Andreas Weinhaeusel; Roman Radl; Peter Krippl; Peter Rehak; Reinhard Windhager; Oskar A Haas; Horst Olschewski
Journal:  Orphanet J Rare Dis       Date:  2006-11-07       Impact factor: 4.123

7.  Neutralizing and IgG antibodies against simian virus 40 in healthy pregnant women in Italy.

Authors:  Manola Comar; Connie Wong; Mauro Tognon; Janet S Butel
Journal:  PLoS One       Date:  2014-10-21       Impact factor: 3.240

8.  Identification of a novel polyomavirus from patients with acute respiratory tract infections.

Authors:  Anne M Gaynor; Michael D Nissen; David M Whiley; Ian M Mackay; Stephen B Lambert; Guang Wu; Daniel C Brennan; Gregory A Storch; Theo P Sloots; David Wang
Journal:  PLoS Pathog       Date:  2007-05-04       Impact factor: 6.823

9.  Simian virus 40 in humans.

Authors:  Fernanda Martini; Alfredo Corallini; Veronica Balatti; Silvia Sabbioni; Cecilia Pancaldi; Mauro Tognon
Journal:  Infect Agent Cancer       Date:  2007-07-09       Impact factor: 2.965

10.  A novel reporter system for neutralizing and enhancing antibody assay against dengue virus.

Authors:  Ke-Yu Song; Hui Zhao; Zhen-You Jiang; Xiao-Feng Li; Yong-Qiang Deng; Tao Jiang; Shun-Ya Zhu; Pei-Yong Shi; Bo Zhang; Fu-Chun Zhang; E-De Qin; Cheng-Feng Qin
Journal:  BMC Microbiol       Date:  2014-02-18       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.